LSTA · CIK 0000320017 · operating
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of therapies for solid tumors and other diseases. The company's primary investigational asset is certepetide, currently in Phase 2 clinical development. Certepetide is being evaluated for treatment across multiple cancer indications, including metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, colon cancer, and glioblastoma multiforme, with studies exploring its use in combination with various anti-cancer regimens.
As a pre-revenue clinical-stage company, Lisata has no established revenue streams from product sales. The company operates with a minimal workforce of 26 full-time employees and is headquartered in Basking Ridge, New Jersey. The company was incorporated in 1980 and is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.40 | $-2.40 | +7.0% | |
| 2023 | $-2.58 | $-2.58 | +75.4% | |
| 2022 | $-10.47 | $-10.47 | -1994.0% | |
| 2021 | $-0.50 | $-0.50 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | $-1.67 | -165.2% | |
| 2017 | $2.56 | $2.56 | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-02-27 | 0000320017-25-000011 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0000320017-24-000007 | SEC ↗ |
| 2022-12-31 | 2023-03-30 | 0000320017-23-000011 | SEC ↗ |
| 2021-12-31 | 2022-03-22 | 0000320017-22-000016 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0000320017-21-000043 | SEC ↗ |
| 2019-12-31 | 2020-03-05 | 0000320017-20-000016 | SEC ↗ |
| 2018-12-31 | 2019-03-14 | 0000320017-19-000024 | SEC ↗ |
| 2017-12-31 | 2018-03-22 | 0000320017-18-000021 | SEC ↗ |
| 2016-12-31 | 2017-03-17 | 0000320017-17-000008 | SEC ↗ |
| 2015-12-31 | 2016-03-15 | 0000320017-16-000098 | SEC ↗ |
| 2014-12-31 | 2015-03-02 | 0000320017-15-000013 | SEC ↗ |
| 2013-12-31 | 2014-03-13 | 0000320017-14-000007 | SEC ↗ |
| 2012-12-31 | 2013-03-11 | 0000320017-13-000009 | SEC ↗ |
| 2011-12-31 | 2012-03-20 | 0001144204-12-016037 | SEC ↗ |
| 2010-12-31 | 2011-04-06 | 0001144204-11-020360 | SEC ↗ |